FE 204205Alternative Names: FE-204205
Latest Information Update: 16 Dec 2016
At a glance
- Originator Ferring Pharmaceuticals
- Mechanism of Action Vasopressin 1a receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ascites; Portal hypertension
Most Recent Events
- 01 Nov 2016 Phase-I clinical trials in Portal hypertension in Spain (IV) (NCT02929407)
- 07 Oct 2016 Ferring Pharmaceuticals plans a phase I trial for Portal hypertension in Spain (IV) (NCT02929407)
- 13 Sep 2016 Preclinical trials in Portal hypertension in Switzerland (IV) before September 2016